Back to News
Oct 24, 2025 8:40 AM

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

Check out LLY stock price here.

Trump Drug Price Reduction Threat Keeps LLY Quality Unfazed

The pharmaceutical giant's climb in operational and financial quality arrives as President Donald Trump pledges to drive "fat-loss drug" prices much lower—a move that sent shares of major GLP-1 drugmakers tumbling in October.

The company, now recognized for its standout operational efficiency and robust financial health, has seen its quality score improve from 89.79 earlier, placing it firmly within the top decline group for quality.

What Does Quality Ranking Entail?

Quality, as measured by the Benzinga Edge Stock Rankings reports, represents a company's operational foundation by analyzing profitability, stability, and key financial ...